australia's next csl?, page-26

G'day All,

Tissue Therapies gets a mention in the "Portfolio" section of the Australian Financial Review today (page 32). Under the heading "Signs of Life" "Near-term milestones to watch" it is listed along with Alchemia (ACL), Impedimed (IPD), Phylogica (PYC), QRxPharma (QRX).

It mentions that TIS's milestone will be "sign licensing deal with large wound care company" in second half calendar year 2011.

The actual article talks about the evolving biotech sector in Australia under the main heading "Biotechs have come of age". A quote from the article says "Investing in this space today is also less risky, since there is a greater diversity of biotechs at different stages of their development. Industry watchers believe the local biotech sector has never looked this good, as Australia has never had as many companies on the cusp of commercialising their technology."

Disclosure: I hold TIS but not the other companies mentioned (although I might "take a bite" of PYC one day).

Regards,

Goggo

DYOR